» Articles » PMID: 33207657

Improving Glucose Homeostasis After Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism with Co-Existing Prediabetes

Overview
Journal Nutrients
Date 2020 Nov 19
PMID 33207657
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

We have previously described increased fasting plasma glucose levels in patients with normocalcemic primary hyperparathyroidism (NPHPT) and co-existing prediabetes, compared to prediabetes per se. This study evaluated the effect of parathyroidectomy (PTx) (Group A), versus conservative follow-up (Group B), in a small cohort of patients with co-existing NPHPT and prediabetes. Sixteen patients were categorized in each group. Glycemic parameters (levels of fasting glucose (fGlu), glycosylated hemoglobin (HbA1c), and fasting insulin (fIns)), the homeostasis model assessment for estimating insulin secretion (HOMA-B) and resistance (HOMA-IR), and a 75-g oral glucose tolerance test were evaluated at baseline and after 32 weeks for both groups. Measurements at baseline were not significantly different between Groups A and B, respectively: fGlu (119.4 ± 2.8 vs. 118.2 ± 1.8 mg/dL, = 0.451), HbA (5.84 ± 0.3 %vs. 5.86 ± 0.4%, = 0.411), HOMA-IR (3.1 ± 1.2 vs. 2.9 ± 0.2, = 0.213), HOMA-B (112.9 ± 31.8 vs. 116.9 ± 21.0%, = 0.312), fIns (11.0 ± 2.3 vs. 12.8 ± 1.4 μIU/mL, = 0.731), and 2-h post-load glucose concentrations (163.2 ± 3.2 vs. 167.2 ± 3.2 mg/dL, = 0.371). fGlu levels demonstrated a positive correlation with PTH concentrations for both groups (Group A, rho = 0.374, = 0.005, and Group B, rho = 0.359, = 0.008). At the end of follow-up, Group A demonstrated significant improvements after PTx compared to the baseline: fGlu ((119.4 ± 2.8 vs. 111.2 ± 1.9 mg/dL, = 0.021) (-8.2 ± 0.6 mg/dL)), and 2-h post-load glucose concentrations ((163.2 ± 3.2 vs. 144.4 ± 3.2 mg/dL, = 0.041), (-18.8 ± 0.3 mg/dL)). For Group B, results demonstrated non-significant differences: fGlu ((118.2 ± 1.8 vs. 117.6 ± 2.3 mg/dL, = 0.031), (-0.6 ± 0.2 mg/dL)), and 2-h post-load glucose concentrations ((167.2 ± 2.7 vs. 176.2 ± 3.2 mg/dL, = 0.781), (+9.0 ± 0.8 mg/dL)). We conclude that PTx for individuals with NPHPT and prediabetes may improve their glucose homeostasis when compared with conservative follow-up, after 8 months of follow-up.

Citing Articles

Turning Points in Cross-Disciplinary Perspective of Primary Hyperparathyroidism and Pancreas Involvements: Hypercalcemia-Induced Pancreatitis, Gene-Related Tumors, and Insulin Resistance.

Carsote M, Nistor C, Gheorghe A, Sima O, Trandafir A, Nistor T Int J Mol Sci. 2024; 25(12).

PMID: 38928056 PMC: 11203827. DOI: 10.3390/ijms25126349.


Association Between Primary Hyperparathyroidism and Secondary Diabetes Mellitus: Findings From a Scoping Review.

Barnett M Cureus. 2023; 15(6):e40743.

PMID: 37350980 PMC: 10284313. DOI: 10.7759/cureus.40743.


The Eucalcemic Patient With Elevated Parathyroid Hormone Levels.

Shaker J, Wermers R J Endocr Soc. 2023; 7(4):bvad013.

PMID: 36793479 PMC: 9922947. DOI: 10.1210/jendso/bvad013.


Normocalcemic primary hyperparathyroidism.

Cusano N, Cetani F Arch Endocrinol Metab. 2022; 66(5):666-677.

PMID: 36382756 PMC: 10118830. DOI: 10.20945/2359-3997000000556.


Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.

Frey S, Bourgade R, Le May C, Croyal M, Bigot-Corbel E, Renaud-Moreau N J Clin Med. 2022; 11(5).

PMID: 35268464 PMC: 8911089. DOI: 10.3390/jcm11051373.


References
1.
Karras S, Koufakis T, Tsekmekidou X, Antonopoulou V, Zebekakis P, Kotsa K . Increased parathyroid hormone is associated with higher fasting glucose in individuals with normocalcemic primary hyperparathyroidism and prediabetes: A pilot study. Diabetes Res Clin Pract. 2019; 160:107985. DOI: 10.1016/j.diabres.2019.107985. View

2.
Dawood N, Yan K, Shieh A, Livhits M, Yeh M, Leung A . Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clin Endocrinol (Oxf). 2020; 93(5):519-527. DOI: 10.1111/cen.14315. View

3.
Lowe H, McMahon D, Rubin M, Bilezikian J, Silverberg S . Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007; 92(8):3001-5. DOI: 10.1210/jc.2006-2802. View

4.
Massry S . Sequence of cellular events in pancreatic islets leading to impaired insulin secretion in chronic kidney disease. J Ren Nutr. 2011; 21(1):92-9. DOI: 10.1053/j.jrn.2010.11.001. View

5.
Beysel S, Caliskan M, Kizilgul M, Apaydin M, Kan S, Ozbek M . Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc Disord. 2019; 19(1):106. PMC: 6505186. DOI: 10.1186/s12872-019-1093-4. View